Lateral Flow Assays, COVID-19, & Emergency Use Authorizations (EUA)

DCN Dx applies their expertise in clinical research to partner with developers of diagnostic devices to achieve EUA approval and then fulfill the clinical testing requirements for normal market clearance. DCN Dx’s clinical research services team prepares your diagnostic device for market approval under EUA and 510(k) conditions. From clinical research to FDA liaising, DCN Dx’s integrated services guide your device to market launch. Download our whitepaper, “Lateral Flow Assays, COVID-19, & Emergency Use Authorizations (EUA),” using the form below to learn more.